Hip Fracture , Postoperative MortalityNCT07495527
Clinical Data-Driven AI Model for Mortality Prediction After Hip Fracture
An observational study of Hip Fracture , Postoperative Mortality, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Hip fractures are a major cause of morbidity and mortality, particularly in elderly patients. Accurate prediction of postoperative mortality is critical for risk stratification and clinical decision-making. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hip Fracture , Postoperative Mortality
- How many people
- 1,000 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Dec 2025to 20 Mar 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study population consists of adult patients who underwent surgical treatment for hip fractures at a tertiary care oncology training and research hospital between January 1, 2022 and December 1, 2025. The cohort is derived retrospectively from electronic health records and includes approximately 1000 patients. The population includes individuals with varying demographic characteristics, comorbidities, and perioperative risk profiles. Clinical data encompass demographic information, baseline functional and cognitive status, comorbid conditions, laboratory parameters, intraoperative variables, and postoperative complications. Patients with malignancy and those undergoing revision surgery are excluded. The study population represents a real-world clinical cohort used to develop and validate an artificial intelligence-based model for predicting 30-day postoperative mortality following hip fracture surgery.
Who may be able to join
- Patients who underwent surgical treatment for hip fracture between January 1, 2022 and December 1, 2025 Age ≥18 years Availability of complete demographic, clinical, and laboratory data in the electronic health record system Documented 30-day follow-up or mortality status
Who cannot join
- Patients with malignancy Patients undergoing revision hip surgery Patients with missing or incomplete key clinical or laboratory data required for analysis Patients with unavailable or undocumented 30-day mortality status
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Ankara, 06200
About this study
Official title: Development of an AI Model Based on Clinical Data to Predict 30-Day and 1-Year Mortality Rates After Hip Fracture Surgery: A Retrospective Cohort Study
Hip fractures are a major cause of morbidity and mortality, particularly in elderly patients. Accurate prediction of postoperative mortality is critical for risk stratification and clinical decision-making. Traditional scoring systems, such as the Nottingham Hip Fracture Score, have limitations in capturing complex, non-linear relationships among clinical variables.
This retrospective cohort study aims to develop and validate an artificial intelligence-based model to predict 30-day mortality in patients undergoing hip fracture surgery. Clinical and laboratory data of approximately 1000 patients operated between January 1, 2022 and December 1, 2025 will be extracted from electronic health records. Variables include demographic characteristics, comorbidities, laboratory parameters, perioperative data, and postoperative complications.
The performance of the artificial intelligence model will be evaluated and compared with conventional risk scoring systems. The study seeks to determine whether AI-based approaches can provide improved predictive accuracy for postoperative mortality in hip fracture patients.
- Conditions
- Hip Fracture , Postoperative Mortality
- Medical subject headings
- Hip Fractures
What is being measured
The primary outcome is the main question the study is designed to answer.
30-Day Postoperative Mortality
All-cause mortality occurring within 30 days following hip fracture surgery, determined from hospital records and electronic health data.
Measured: 30 days after surgery and 1 year later
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2026
- Study start1 Dec 2025
- Primary completion10 Mar 2026
- Study completion20 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Hip Fracture , Postoperative MortalityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rahimegül Yekebaş Elma, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07495527
- Sponsor's protocol ID
- 2025-12/209
- Status last verified
- Mar 2026
- First submitted
- 21 Mar 2026
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to the retrospective nature of the study and the inclusion of sensitive patient information obtained from electronic health records. All data will be analyzed in an anonymized form, and data sharing is restricted in accordance with institutional policies and ethical regulations
Publications
Ju M, Lee S, Marvich HM, Lin S. Accessing Alkoxy Radicals via Frustrated Radical Pairs: Diverse Oxidative Functionalizations of Tertiary Alcohols. J Am Chem Soc. 2024 Jul 24;146(29):19696-19703. doi: 10.1021/jacs.4c07125. Epub 2024 Jul 16.
PubMed 39012345Wanchaijiraboon P, Sainamthip P, Teeyapun N, Luangdilok S, Poovorawan Y, Wanlapakorn N, Tanasanvimon S, Sriuranpong V, Susiriwatananont T, Zungsontiporn N, Pakvisal N. Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac. Vaccines (Basel). 2023 Feb 3;11(2):356. doi: 10.3390/vaccines11020356.
PubMed 36851234Gonzalez Martinez J, Chen JJ, Aung T, Constantine T, Gonzalez-Martinez JA. Comparative Feasibility and Complication Analyses of Extraoperative (Bedside) Removal of Stereo-Electroencephalography Electrodes. Stereotact Funct Neurosurg. 2025;103(5):302-311. doi: 10.1159/000545984. Epub 2025 Apr 23.
PubMed 40267891
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of an AI Model Based on Clinical Data to Predict 30-Day and 1-Year Mortality Rates After Hip Fracture Surgery: A Retrospective Cohort Study
- ClinicalTrials.gov ID
- NCT07495527
- Acronym / sponsor ID
- 2025-12/209
- Conditions
- Hip Fracture , Postoperative Mortality
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalUniversity, hospital or other
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- 10 Mar 2026 (actual)
- Study completion
- 20 Mar 2026 (actual)
- First posted
- 27 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hip fractures are a major cause of morbidity and mortality, particularly in elderly patients. Accurate prediction of postoperative mortality is critical for risk stratification and clinical decision-making. Traditional scoring systems, such as the Nottingham Hip Fracture Score, have limitations in capturing complex, non-linear relationships among clinical variables.
This retrospective cohort study aims to develop and validate an artificial intelligence-based model to predict 30-day mortality in patients undergoing hip fracture surgery. Clinical and laboratory data of approximately 1000 patients operated between January 1, 2022 and December 1, 2025 will be extracted from electronic health records. Variables include demographic characteristics, comorbidities, laboratory parameters, perioperative data, and postoperative complications.
The performance of the artificial intelligence model will be evaluated and compared with conventional risk scoring systems. The study seeks to determine whether AI-based approaches can provide improved predictive accuracy for postoperative mortality in hip fracture patients.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study population consists of adult patients who underwent surgical treatment for hip fractures at a tertiary care oncology training and research hospital between January 1, 2022 and December 1, 2025. The cohort is derived retrospectively from electronic health records and includes approximately 1000 patients. The population includes individuals with varying demographic characteristics, comorbidities, and perioperative risk profiles. Clinical data encompass demographic information, baseline functional and cognitive status, comorbid conditions, laboratory parameters, intraoperative variables, and postoperative complications. Patients with malignancy and those undergoing revision surgery are excluded. The study population represents a real-world clinical cohort used to develop and validate an artificial intelligence-based model for predicting 30-day postoperative mortality following hip fracture surgery.
Key inclusion criteria (1 listed)
- Patients who underwent surgical treatment for hip fracture between January 1, 2022 and December 1, 2025 Age ≥18 years Availability of complete demographic, clinical, and laboratory data in the electronic health record system Documented 30-day follow-up or mortality status
Key exclusion criteria (1 listed)
- Patients with malignancy Patients undergoing revision hip surgery Patients with missing or incomplete key clinical or laboratory data required for analysis Patients with unavailable or undocumented 30-day mortality status
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
30-Day Postoperative Mortality
Time frame: 30 days after surgery and 1 year later
All-cause mortality occurring within 30 days following hip fracture surgery, determined from hospital records and electronic health data.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
- Background: PubMed 39012345Ju M, Lee S, Marvich HM, Lin S. Accessing Alkoxy Radicals via Frustrated Radical Pairs: Diverse Oxidative Functionalizations of Tertiary Alcohols. J Am Chem Soc. 2024 Jul 24;146(29):19696-19703. doi: 10.1021/jacs.4c07125. Epub 2024 Jul 16.
- Background: PubMed 36851234Wanchaijiraboon P, Sainamthip P, Teeyapun N, Luangdilok S, Poovorawan Y, Wanlapakorn N, Tanasanvimon S, Sriuranpong V, Susiriwatananont T, Zungsontiporn N, Pakvisal N. Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac. Vaccines (Basel). 2023 Feb 3;11(2):356. doi: 10.3390/vaccines11020356.
- Background: PubMed 40267891Gonzalez Martinez J, Chen JJ, Aung T, Constantine T, Gonzalez-Martinez JA. Comparative Feasibility and Complication Analyses of Extraoperative (Bedside) Removal of Stereo-Electroencephalography Electrodes. Stereotact Funct Neurosurg. 2025;103(5):302-311. doi: 10.1159/000545984. Epub 2025 Apr 23.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to the retrospective nature of the study and the inclusion of sensitive patient information obtained from electronic health records. All data will be analyzed in an anonymized form, and data sharing is restricted in accordance with institutional policies and ethical regulations
Related trials for Hip Fracture , Postoperative Mortality
Not yet recruitingObservational study
GNRI and Rectus Femoris Muscle Thickness in Older Patients Undergoing Hip Fracture Surgery
Hip Fracture, Malnutrition
RecruitingObservational study
Prediction of Mortality and Morbidity After Hip Fracture Using Monocyte Distribution Width (MDW)
Sepsis, Osteoporotic Hip Fracture
Not yet recruiting
Preoperative Analgesia: The Effectiveness of the PENG Block in Patients With Hip Fractures
Hip Fracture Surgeries
RecruitingObservational study
The Effects of Anesthesia Type on the Prognosis of Hip Fracture Surgery on Elderly Patients
Postoperative Complications, Postoperative Mortality
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hip Fracture , Postoperative Mortality, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
30-Day Postoperative Mortality (time frame: 30 days after surgery and 1 year later). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07495527, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.